<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01462708</url>
  </required_header>
  <id_info>
    <org_study_id>CB1-01</org_study_id>
    <nct_id>NCT01462708</nct_id>
  </id_info>
  <brief_title>Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects</brief_title>
  <acronym>MK9470</acronym>
  <official_title>Evaluation of [18F] MK-9470 and PET as a Marker of Cannabinoid-1 Receptor Activity in Subjects With Parkinson Disease Compared With Healthy Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Neurodegenerative Disorders</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Neurodegenerative Disorders</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess MK-9470 Positron Emission Tomography (PET) imaging as&#xD;
      a tool to evaluate the activity of the CB-1 receptor in the brain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The underlying goal of this study is to assess MK-9470 PET imaging as a tool to evaluate the&#xD;
      activity of the CB-1 receptor in the brain of Parkinson's Disease (PD) research participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dynamic uptake and washout of [18F]MK-9470</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>To assess the dynamic uptake and washout of [18F]-MK-9470 in brain using positron emission tomography (PET) in early Parkinson disease and advanced Parkinson disease with and without dyskinesia and similarly aged healthy control subjects as a potential imaging biomarker of the cannabionoid-1 (CB-1) receptor in brain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To acquire safety data</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Safety will be assessed by the number of adverse events experienced by subjects and any clinically significant changes in laboratory tests or vital signs.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Assess [18F]MK-9470 and PET imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To Assess [18F]MK-9470 and PET imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]MK-9470</intervention_name>
    <description>Subjects will be injected with 10 mCi, and not to exceed 11 mCi (not &gt;10% of 10 mCi limit)of [18F]MK-9470, followed by PET imaging.</description>
    <arm_group_label>Assess [18F]MK-9470 and PET imaging</arm_group_label>
    <other_name>Parkinson Disease</other_name>
    <other_name>Cannabinoid-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Early PD Subjects&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  The participant is 30 years or older.&#xD;
&#xD;
          -  Written informed consent is obtained.&#xD;
&#xD;
          -  Participants have a diagnosis of PD (based on UK Brain Bank Criteria) within the past&#xD;
             2 years.&#xD;
&#xD;
          -  Modified Hoehn and Yahr stages 1-2.&#xD;
&#xD;
          -  No evidence of dyskinesia by history or clinical examination&#xD;
&#xD;
          -  For females, non-child bearing potential or a negative urine or blood pregnancy test&#xD;
             on day of [18F]-MK-9470 injection.&#xD;
&#xD;
        Advanced PD subjects&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  The participant is 30 years or older.&#xD;
&#xD;
          -  Written informed consent is obtained.&#xD;
&#xD;
          -  Participants have a diagnosis of PD (based on UK Brain Bank Criteria) of at least 5&#xD;
             years duration.&#xD;
&#xD;
          -  Modified Hoehn and Yahr stages 1-4.&#xD;
&#xD;
          -  No evidence of dyskinesia by history or clinical examination&#xD;
&#xD;
          -  For females, non-child bearing potential or a negative urine or blood pregnancy test&#xD;
             on day of [18F]-MK-9470 injection.&#xD;
&#xD;
        Subjects who have a clinical diagnosis of advanced PD with dyskinesia will be recruited for&#xD;
        this study.&#xD;
&#xD;
        ePD subjects&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  The participant is 30 years or older.&#xD;
&#xD;
          -  Written informed consent is obtained.&#xD;
&#xD;
          -  Participants have a diagnosis of PD (based on UK Brain Bank Criteria) of at least 5&#xD;
             years.&#xD;
&#xD;
          -  Modified Hoehn and Yahr stages 1-4.&#xD;
&#xD;
          -  Evidence of dyskinesia either by history or clinical examination&#xD;
&#xD;
          -  For females, non-child bearing potential or a negative urine or blood pregnancy test&#xD;
             on day of [18F]-MK-9470 injection.&#xD;
&#xD;
        PD (all stages- e-PD, aPD, aPD-dys)Subject Selection. Subjects who have a clinical&#xD;
        diagnosis of ePD, aPD, aPD-dys will be recruited for this study.&#xD;
&#xD;
        All PD subjects&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  The subject has a clinically significant abnormal laboratory value and/or clinically&#xD;
             significant unstable medical or psychiatric illness&#xD;
&#xD;
          -  The subject has any disorder that may interfere with drug absorption, distribution,&#xD;
             metabolism, or excretion.&#xD;
&#xD;
          -  The patient has evidence of unstable gastrointestinal, cardiovascular, hepatic, renal,&#xD;
             hematological, neoplastic, endocrine, neurological, pulmonary, or other disorder or&#xD;
             disease.&#xD;
&#xD;
          -  Evidence of a stroke or mass lesion in a clinically relevant area that may interfere&#xD;
             with the imaging outcome measure&#xD;
&#xD;
          -  Subjects with radiation exposure above acceptable levels&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
        Healthy Control Subject Selection: subjects who have no neurological disease will be&#xD;
        recruited for this study.&#xD;
&#xD;
        Healthy control subjects&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  The participant is 18 years or older.&#xD;
&#xD;
          -  Written informed consent is obtained.&#xD;
&#xD;
          -  Negative history of neurological or psychiatric illness based on evaluation by a&#xD;
             research physician.&#xD;
&#xD;
          -  For females, non-child bearing potential a negative urine or blood pregnancy test on&#xD;
             day of [18F]-MK9470 injection.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  The subject has a clinically significant abnormal laboratory value and/or clinically&#xD;
             significant unstable medical or psychiatric illness.&#xD;
&#xD;
          -  The subject has evidence of clinically significant gastrointestinal, cardiovascular,&#xD;
             hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency,&#xD;
             pulmonary, or other disorder or disease.&#xD;
&#xD;
          -  The subject has any disorder that may interfere with drug absorption, distribution,&#xD;
             metabolism, or excretion.&#xD;
&#xD;
          -  Subjects with radiation exposure above acceptable levels&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danna Jennings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Neurodegenerative Disorders</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.indd.org</url>
    <description>Institute for Neurodegenerative Disorders</description>
  </link>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>October 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2011</study_first_posted>
  <last_update_submitted>November 8, 2013</last_update_submitted>
  <last_update_submitted_qc>November 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Neurodegenerative Disorders</investigator_affiliation>
    <investigator_full_name>Danna Jennings, MD</investigator_full_name>
    <investigator_title>Danna Jennings, MD</investigator_title>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <keyword>Molecular NeuroImaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

